Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000097:blood / Q000188:drug therapy*; D014408:Biomarkers, Tumor / Q000097:blood*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000097:blood / Q000235:genetics; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D011237:Predictive Value of Tests; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000097:blood / Q000235:genetics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D016159:Tumor Suppressor Protein p53; D001241:Aspirin